Wave Life Sciences
Logotype for Wave Life Sciences Ltd

Wave Life Sciences (WVE) investor relations material

Wave Life Sciences R&D Day 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Wave Life Sciences Ltd
R&D Day 2026 summary4 Nov, 2026

Pipeline overview and program updates

  • WVE-008 is a GalNAc-conjugated RNA editing candidate designed to correct the PNPLA3 I148M mutation and restore normal PNPLA3 function.

  • WVE-007 is an INHBE siRNA in Phase II; plans include a maintenance trial and 600 mg INLIGHT cohort data, with durable suppression supporting potential once- or twice-yearly dosing.

  • SpiNA and PN conjugates aim to extend RNAi activity and deliver medicines to extrahepatic tissues, including adipose and kidney.

  • Bifunctional oligonucleotides combine silencing, editing, or upregulation of distinct RNA targets in one construct.

Clinical trial data and development milestones

  • WVE-008 preclinical studies showed potent, specific editing, reduced hepatocyte fat, distribution across liver zones, and over 60% editing in mouse hepatic stellate cells.

  • The WVE-008 clinical candidate achieved up to 85% hepatocyte editing; the program aims to edit at least 50% of PNPLA3 transcripts.

  • A single 240 mg WVE-007 dose was associated at six months with placebo-adjusted visceral fat reduction of 14%, waist reduction of 3%, and lean-mass stabilization of 2%; Activin E suppression lasted at least seven months.

  • The first-in-human WVE-008 study is planned to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in homozygous carriers; WVE-007 Phase 2a multidose INLIGHT is enrolling people with higher baseline adiposity and comorbidities.

  • Preclinical PN-conjugate/SpiNA data showed 75% SOD1 mRNA knockdown and sustained 50% knockdown up to three months after one dose.

R&D strategy and innovation priorities

  • The Oligonucleotide Center of Excellence and PRISM platform integrate human genetics, modality selection, rational design, predictive models, manufacturing, and cross-program learning.

  • SpiNA GalNAc-siRNAs showed over 10-fold greater AGO2 loading than reference siRNAs; one dose produced durable PCSK9 reduction through at least day 56.

  • PN conjugate chemistry is being tuned for tissue-specific delivery without LNPs or other delivery agents; preclinical constructs achieved up to 90% adipose knockdown, and a kidney-directed variant reduced SOD1 mRNA 75% in mice.

  • Bifunctional designs demonstrated simultaneous target silencing and RNA editing or upregulation; LPA-PCSK9 SpiNA lowered both targets, and a silencing/upregulation construct achieved over fivefold target Y upregulation in vivo.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Wave Life Sciences earnings date

Logotype for Wave Life Sciences Ltd
Jefferies Global Healthcare Conference18 Nov, 2026
Wave Life Sciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Wave Life Sciences earnings date

Logotype for Wave Life Sciences Ltd
Jefferies Global Healthcare Conference18 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Wave Life Sciences Ltd. (WVE) is a biotechnology company leveraging its proprietary RNA medicines platform, PRISM, to develop transformative treatments for a range of genetic diseases. This platform enables the design, optimization, and production of novel stereopure oligonucleotides, aimed at correcting disease-causing mutations, modulating protein activity, and restoring functional protein production or reducing disease-promoting RNAs or proteins. Wave's diverse pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington's disease, and a preclinical program for obesity, among others. Their approach includes multiple RNA-targeting modalities such as editing, splicing, RNA interference, and antisense silencing, showcasing their broad capabilities in addressing complex disease biology. The company is headquartered in Singapore, and its shares are listed on the Nasdaq.